CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob L who wrote (577)	5/26/2000 6:39:00 PM
From: Bob L	of 666

What strikes me in this study is the relatively high platelet nadir at 83,000, even though 64% of the patients in this newer study had bone marrow involvement. This is much better than the patients in the phase III experienced. At the time of the the phase III results, Coulter claimed that the "heavy pretreatment" of these patients with chemo contributed to the more severe drop in blood counts. Now it appears they may have been correct. More good results for Bexxar. Now if they could just develop a treatment for truth-impairment, we could find out what is really going on with the BLA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next